Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?
Ann Rheum Dis
.
2021 Jan;80(1):e6.
doi: 10.1136/annrheumdis-2020-217556.
Epub 2020 Apr 21.
Authors
Wenhui Xie
1
,
Yu Wang
1
,
Zhuoli Zhang
2
Affiliations
1
Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China.
2
Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China zhuoli.zhang@126.com.
PMID:
32317316
DOI:
10.1136/annrheumdis-2020-217556
No abstract available
Keywords:
autoimmune diseases; hydroxychloroquine; outcome assessment, health care.
Publication types
Letter
Comment
MeSH terms
COVID-19*
Humans
Hydroxychloroquine / therapeutic use
Rheumatic Diseases* / drug therapy
Risk Factors
SARS-CoV-2
Substances
Hydroxychloroquine